• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Spaulding Clinical Research partners with Clinigene

Spaulding Clinical Research partners with Clinigene

August 23, 2011
CenterWatch Staff

Spaulding Clinical Research has partnered with Clinigene International, part of the Biocon, based in Bangalore, India, to broaden and globalize its research services offering, according to PharmaTimes.

The strategic partnership with Clinigene International establishes a “reliable, trustworthy, and cost-efficient global footprint for clinical pharmacology services,” giving both companies an opportunity to “engage pharmaceutical clients strategically and accelerate first-in-human to proof-of-concept clinical development,” Spaulding said.

While Clinigene can offer preclinical development services through its sister-company Syngene, Spaulding will cover the FIH/SAD/MAD (first in human/ single ascending dose/multiple ascending dose) end.

Clinigene also provides DDI (drug-drug interaction) and proof-of-concept services, backed up by its central and bioanalytical laboratories.

“With Clinigene’s expertise and cost-effective approach to BA/BE [bioavailability.bioequivalence] and Spaulding’s market-leading TQT [cardiac risk] study and Cardiac Core Lab expertise, our clients are able to easily structure a program for their compound that delivers high-value while keeping the molecule knowledge experts involved throughout the entire early clinical development of the compound,” said  Randol Spaulding, chief executive officer of Spaulding Clinical.

Upcoming Events

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

  • 06May

    The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

  • 25May

    How Can the Accelerated Availability of Pfizer-BioNTech’s COVID-19 Vaccine be Replicated?

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Clinical-Trial-Brainstorming

    FDA, Industry Tackle Problem of Including Older Adults in Trials

  • ClinicalTrialNetwork-360x240.png

    National Community-Based Research Network Would Improve Reach of Trials

  • Bottleneck-360x240.png

    Sites Face Trials Bottleneck After Pandemic, But Also Opportunities

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Genetic Research and IBC Oversight Requirements

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing